Tilray Brands
Tilray Brands' revenue rose 11.5% to $916 million in fiscal 2026. Its operating margin was −6.9%, up from −277.9% a year earlier. The diluted share count rose 25.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Tilray Brands lost money in fiscal 2026: a net loss of $121 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 416 | 448 | 260 | 256 | 231 |
| Debt incl. finance leases | 204 | 419 | 193 | 140 | 213 |
| Net debt (negative means net cash) | −212 | −30 | −68 | −117 | −18 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.1x | 0.1x | 0.1x | 0.1x | 0.1x |
| Interest coverage | −15.4x | −29.4x | −3.5x | −55.2x | −2.1x |
| Current ratio | 2.9x | 1.8x | 2.3x | 2.5x | 2.2x |
| Quick ratio | 2.0x | 1.3x | 1.4x | 1.5x | 1.4x |
Cash flow
Projections
Project Tilray Brands' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 3 insiders bought $69,225 of Tilray Brands shares on the open market, and 1 insider sold $232,879.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Mitchell GendelGlobal General Counsel | Bought | 2,500 | $4.43 | $11,075 | Form 4 |
| Aug 4, 2026 | Carl A MertonChief Financial Officer | Bought | 10,000 | $4.62 | $46,200 | Form 4 |
| Aug 3, 2026 | Denise M FaltischekChief Strategy Officer | Bought | 2,500 | $4.78 | $11,950 | Form 4 |
| Apr 21, 2026 | David G. HopkinsonDirector | Sold | 33,556 | $6.94 | $232,879 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 | FY26 |
|---|---|---|---|
| Piotroski F-score | 6 of 9 | 5 of 9 | 3 of 9 |
| Rule of 40 | 18.2% | −11.4% | — |
| Altman Z'' | 2.90 | −11.05 | −3.63 |
| Accruals ratio | −5.0% | −66.5% | −2.4% |
The nine F-score tests
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Pass | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 6 of 9 | 5 of 9 | 3 of 9 |
Compare
Put Tilray Brands side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Tilray Brands | FY26 | 11.5% | −6.9% | — | −3.4% | — | 3 | |
| Ionis Pharmaceuticals | FY25 | 33.8% | −40.5% | −33.9% | — | — | 3 | Compare |
| ANI Pharmaceuticals | FY25 | 43.8% | 12.6% | 19.4% | 15.9% | 0.1x | 6 | Compare |
| Madrigal Pharmaceuticals | FY25 | 432.1% | −31.3% | −19.8% | — | — | 3 | Compare |
| Telix Pharmaceuticals | FY25 | 55.6% | 3.7% | −5.3% | 5.0% | 5.1x | 2 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 20 | 43 | 167 | 210 | 513 | 628 | 627 | 789 | 821 | 916 |
| Revenue growth | 62.4% | 110.0% | 287.1% | 26.1% | 143.8% | 22.5% | −0.2% | 25.8% | 4.1% | 11.5% |
| Gross profit | 11 | 14 | −24 | 25 | 123 | 117 | 147 | 223 | 241 | 260 |
| Research and development | 3 | 6 | 9 | 4 | 1 | 2 | 1 | 1 | 0 | 0 |
| Operating income | −8 | −58 | −304 | −201 | −132 | −610 | −1,370 | −175 | −2,283 | −63 |
| Net income | −8 | −68 | −321 | −271 | −367 | −477 | −1,453 | −245 | −2,187 | −121 |
| Diluted EPS (US$) | −1.00 | −8.20 | −32.00 | −21.50 | −13.60 | −9.90 | −23.50 | −3.30 | −24.56 | −1.09 |
| Diluted shares (millions) | 8 | 8 | 10 | 13 | 27 | 48 | 62 | 74 | 89 | 112 |
| Cash flow | ||||||||||
| Cash from operations | −6 | −46 | −258 | −129 | −45 | −177 | 8 | −31 | −95 | −69 |
| Capital expenditure | 11 | 50 | 74 | 45 | 39 | 34 | 21 | 29 | 33 | — |
| Free cash flow | −17 | −96 | −332 | −174 | −84 | −211 | −13 | −60 | −128 | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 164 | 0 | 67 | 0 | 27 | 61 | 18 | 54 |
| Stock-based compensation | 0 | 21 | 32 | 30 | 17 | 36 | 40 | 32 | 24 | 46 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | 518 | — | 190 | 488 | 416 | 448 | 260 | 256 | 231 |
| Debt incl. finance leases | 9 | — | — | — | 249 | 204 | 419 | 193 | 140 | 213 |
| Total assets | 54 | 657 | 896 | 946 | 6,025 | 5,450 | 4,307 | 4,222 | 2,074 | 2,328 |
| Total liabilities | 59 | 459 | 611 | 572 | 1,560 | 1,008 | 977 | 778 | 585 | 733 |
| Shareholders' equity | −5 | 198 | 285 | 374 | 4,459 | 4,399 | 3,316 | 3,443 | 1,512 | 1,614 |
| Margins and ratios | ||||||||||
| Gross margin | 55.4% | 33.1% | −14.1% | 11.7% | 24.0% | 18.6% | 23.4% | 28.3% | 29.3% | 28.4% |
| Operating margin | −36.5% | −134.1% | −182.1% | −95.5% | −25.8% | −97.1% | −218.4% | −22.1% | −277.9% | −6.9% |
| Net margin | −38.0% | −157.0% | −192.3% | −128.8% | −71.6% | −75.9% | −231.6% | −31.1% | −266.2% | −13.3% |
| Free cash flow margin | −82.3% | −223.6% | −198.7% | −82.7% | −16.3% | −33.6% | −2.1% | −7.6% | −15.5% | — |
| Rule of 40 (growth + FCF margin) | −19.9% | −113.6% | 88.4% | −56.6% | 127.5% | −11.2% | −2.2% | 18.2% | −11.4% | — |
| Return on capital | — | — | — | — | — | −11.4% | −28.7% | −4.1% | −76.0% | −3.4% |
| Return on equity | — | −70.2% | −133.0% | −82.2% | −15.2% | −10.8% | −37.7% | −7.2% | −88.3% | −7.8% |
| Return on assets | — | −19.1% | −41.4% | −29.4% | −10.5% | −8.3% | −29.8% | −5.7% | −69.5% | −5.5% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |